My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 9 590 / https://doi.org/10.3332/ecancer.2015.590

Case Report

Myxoid mesenchymal neoplasm presenting as massive arm and chest wall oedema with pleural effusion

Myxoid mesenchymal tumours are a heterogeneous group of neoplasms characterised histologically by their abundant mucoid and myxoid extracellular matrix (ECM). Encompassing a broad spectrum of clinical behaviour ranging from benign to malignant, there are more than 60 reactive and neoplastic entities currently classified under its domain. Its varied clinical and histopathologic features continue to pose a diagnostic challenge to clinicians and pathologists. Here, we describe a rare case of myxoid mesenchymal tumour presenting as oedema of the upper extremity with pleural metastasis and partial response to chemotherapy, which to the best of our knowledge has not yet been described in the literature.

Keywords: extracellular matrix, malignant pleural effusion, neoplasms, sarcoma

Loading Article Metrics ... Please wait

Related articles

Special Issue: Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come

Abstract | Full Article | PDF Published: 30 Nov 2017 / https://doi.org/10.3332/ecancer.2017.787

Special Issue: Acute myeloid leukaemia at an early age: Reviewing the interaction between pesticide exposure and KMT2A-rearrangment

Abstract | Full Article | PDF Published: 30 Nov 2017 / https://doi.org/10.3332/ecancer.2017.782

Clinical Study: Prognostic value of a patient-reported functional score versus physician-reported Karnofsky Performance Status Score in brain metastases

Abstract | Full Article | PDF Published: 10 Nov 2017 / https://doi.org/10.3332/ecancer.2017.779

Case Report: Retromammary fat, axillary and arm metastases from a retroperitoneal leiomyosarcoma: report of a case with an indolent behaviour

Abstract | Full Article | PDF Published: 31 Oct 2017 / https://doi.org/10.3332/ecancer.2017.778

Clinical Study: Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy

Abstract | Full Article | PDF Published: 24 Oct 2017 / https://doi.org/10.3332/ecancer.2017.776



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence